Masaoki Ito

1.4k total citations
60 papers, 820 citations indexed

About

Masaoki Ito is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Masaoki Ito has authored 60 papers receiving a total of 820 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Masaoki Ito's work include Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Lung Cancer Research Studies (10 papers). Masaoki Ito is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Lung Cancer Research Studies (10 papers). Masaoki Ito collaborates with scholars based in Japan, Spain and Italy. Masaoki Ito's co-authors include Yoshihiro Miyata, Morihito Okada, Yasuhiro Tsutani, Rafael Rosell, Niki Karachaliou, Keizo Misumi, Jordi Codony‐Servat, Jordi Berenguer, Jillian Wilhelmina Paulina Bracht and Morihito Okada and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Masaoki Ito

57 papers receiving 811 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Masaoki Ito Japan 17 433 300 289 136 101 60 820
Yongfeng Yu China 17 395 0.9× 411 1.4× 368 1.3× 197 1.4× 76 0.8× 64 844
Clorinda Schettino Italy 18 462 1.1× 508 1.7× 425 1.5× 157 1.2× 65 0.6× 37 982
Woo Sun Kwon South Korea 16 271 0.6× 401 1.3× 267 0.9× 128 0.9× 89 0.9× 51 677
Daisaku Morita Japan 11 310 0.7× 274 0.9× 343 1.2× 138 1.0× 145 1.4× 20 809
Alan D. Smith United Kingdom 14 361 0.8× 236 0.8× 234 0.8× 171 1.3× 63 0.6× 35 635
David James VanderWeele United States 15 355 0.8× 300 1.0× 485 1.7× 262 1.9× 57 0.6× 57 1.0k
Cor van der Leest Netherlands 11 408 0.9× 296 1.0× 559 1.9× 246 1.8× 50 0.5× 28 981
Ling Gao United States 15 317 0.7× 343 1.1× 207 0.7× 57 0.4× 105 1.0× 46 633
Wei Jing China 16 199 0.5× 269 0.9× 341 1.2× 111 0.8× 68 0.7× 45 694
Yusuke Imamura Japan 15 399 0.9× 154 0.5× 315 1.1× 169 1.2× 95 0.9× 77 765

Countries citing papers authored by Masaoki Ito

Since Specialization
Citations

This map shows the geographic impact of Masaoki Ito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masaoki Ito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masaoki Ito more than expected).

Fields of papers citing papers by Masaoki Ito

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masaoki Ito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masaoki Ito. The network helps show where Masaoki Ito may publish in the future.

Co-authorship network of co-authors of Masaoki Ito

This figure shows the co-authorship network connecting the top 25 collaborators of Masaoki Ito. A scholar is included among the top collaborators of Masaoki Ito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masaoki Ito. Masaoki Ito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Suda, Kenichi, Akira Hamada, Toshio Fujino, et al.. (2025). Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study. Cells. 14(17). 1386–1386.
2.
Suda, Kenichi, Akira Hamada, Shuta Ohara, et al.. (2024). Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study. Biomedicines. 12(7). 1412–1412. 6 indexed citations
3.
Ohara, Shuta, Kenichi Suda, Akira Hamada, et al.. (2024). Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer. Thoracic Cancer. 15(31). 2229–2234. 1 indexed citations
4.
Tomoshige, Koichi, William D. Stuart, Masaoki Ito, et al.. (2023). FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung. Cancer Research. 83(9). 1443–1458. 4 indexed citations
5.
Hamada, Akira, Kenichi Suda, Masaya Nishino, et al.. (2023). Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion. Journal of Thoracic Oncology. 19(1). 71–79. 9 indexed citations
6.
Ito, Masaoki, Yoshihiro Miyata, & Morihito Okada. (2023). Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: A systematic review. Translational Oncology. 31. 101634–101634. 27 indexed citations
7.
8.
Ito, Masaoki, et al.. (2023). Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC. JTO Clinical and Research Reports. 4(12). 100604–100604. 3 indexed citations
9.
Tsutani, Yasuhiro, Masaoki Ito, Yoshihisa Shimada, et al.. (2022). The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery. 164(5). 1306–1315.e4. 16 indexed citations
10.
Handa, Yoshinori, Yasuhiro Tsutani, Masaoki Ito, et al.. (2021). Clinical Behavior of Combined Versus Pure High-Grade Neuroendocrine Carcinoma. Clinical Lung Cancer. 23(1). e9–e16.e1. 3 indexed citations
11.
Ito, Masaoki, Yasuhiro Tsutani, Ana Giménez‐Capitán, et al.. (2021). Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung. Journal of Cancer Research and Clinical Oncology. 147(12). 3709–3718. 11 indexed citations
12.
Rosell, Rafael, Andrés F. Cardona, Óscar Arrieta, et al.. (2021). Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. British Journal of Cancer. 125(12). 1602–1611. 31 indexed citations
13.
Ito, Masaoki, Yoshihiro Miyata, Kyoko Ikeda, et al.. (2019). Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology. 145(9). 2325–2333. 7 indexed citations
14.
Mimae, Takahiro, Masaoki Ito, Takayuki Kadoya, et al.. (2019). Breast cancer cell motility is promoted by 14-3-3γ. Breast Cancer. 26(5). 581–593. 15 indexed citations
15.
Tsutani, Yasuhiro, et al.. (2018). P2.01-97 Prognostic Factors in Resected Lung Mucinous Adenocarcinoma: Clinical and Pathological Features. Journal of Thoracic Oncology. 13(10). S702–S702. 2 indexed citations
16.
Ito, Masaoki, Yoshihiro Miyata, & Morihito Okada. (2018). Management pathways for solitary pulmonary nodules. Journal of Thoracic Disease. 10(S7). S860–S866. 13 indexed citations
17.
Tsutani, Yasuhiro, Takeshi Mimura, Yuichiro Kai, et al.. (2017). OA15.03 Comparison of Prognosis between Lobectomy and Sublobar Resection for Clinical Stage I Non-Small Cell Lung Cancer with Interstitial Lung Disease. Journal of Thoracic Oncology. 12(1). S302–S302. 1 indexed citations
18.
Tsutani, Yasuhiro, Takeshi Mimura, Yuichiro Kai, et al.. (2017). Outcomes after lobar versus sublobar resection for clinical stage I non−small cell lung cancer in patients with interstitial lung disease. Journal of Thoracic and Cardiovascular Surgery. 154(3). 1089–1096.e1. 40 indexed citations
19.
Karachaliou, Niki, Aaron E. Sosa, Jordi Berenguer, et al.. (2017). The combination of checkpoint immunotherapy and targeted therapy in cancer. Annals of Translational Medicine. 5(19). 388–388. 54 indexed citations
20.
Yoshiya, Tomoharu, Masaoki Ito, Keizo Misumi, et al.. (2016). The effect of rikkunshito, a traditional Japanese herbal medicine, on food intake and plasma acylated ghrelin levels in lung cancer patients treated with platinum-based chemotherapy. Annals of Oncology. 27. vi510–vi510. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yongfeng Yu Breakdown of academic impact, for papers by Clorinda Schettino Breakdown of academic impact, for papers by Woo Sun Kwon Breakdown of academic impact, for papers by Daisaku Morita Breakdown of academic impact, for papers by Alan D. Smith Breakdown of academic impact, for papers by David James VanderWeele Breakdown of academic impact, for papers by Cor van der Leest Breakdown of academic impact, for papers by Ling Gao Breakdown of academic impact, for papers by Wei Jing Breakdown of academic impact, for papers by Yusuke Imamura
Rankless by CCL
2026